Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways

Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation

(2011) Bjoern Chapuy et al.   BRITISH JOURNAL OF HAEMATOLOGY

Overcoming Chemotherapy Resistance in Prostate Cancer

(2011) R. A. Madan et al.   CLINICAL CANCER RESEARCH

Androgen receptor levels are upregulated by Akt in prostate cancer

(2011) S. Ha et al.   ENDOCRINE-RELATED CANCER

Sorafenib Enhances the Antitumor Effects of Chemoradiation Treatment by Downregulating ERCC-1 and XRCC-1 DNA Repair Proteins

(2011) A. Yadav et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines

(2011) F. R. Santer et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib Sensitizes (-)-Gossypol-Induced Growth Suppression in Androgen-Independent Prostate Cancer Cells via Mcl-1 Inhibition and Bak Activation

(2011) J. Lian et al.   MOLECULAR CANCER THERAPEUTICS

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells

(2010) Rui Huang et al.   ASIAN JOURNAL OF ANDROLOGY

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Class III  -Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

(2010) G. Ploussard et al.   CANCER RESEARCH

In Vitro and In Vivo Antitumor Efficacy of Docetaxel and Sorafenib Combination in Human Pancreatic Cancer Cells

(2010) P. Ulivi et al.   CURRENT CANCER DRUG TARGETS

SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling

(2010) Martin Puhr et al.   ENDOCRINE-RELATED CANCER

Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo

(2010) Gang Wei et al.   INTERNATIONAL JOURNAL OF CANCER

Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro

(2010) Ullén   INTERNATIONAL JOURNAL OF ONCOLOGY

Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells

(2010) S. Huang et al.   MOLECULAR CANCER THERAPEUTICS

Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer

(2009) Jeanny B. Aragon-Ching et al.   BJU INTERNATIONAL

Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A

(2009) Andreas Desiniotis et al.   INTERNATIONAL JOURNAL OF CANCER

PTENgenomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer

(2009) Kanishka Sircar et al.   JOURNAL OF PATHOLOGY

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer

(2008) G. Gravis et al.   ANNALS OF ONCOLOGY

A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer

(2008) W. L. Dahut et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Sunitinib for the Therapy of Progressive Metastatic Castration-Refractory Prostate Cancer After Previous Docetaxel Chemotherapy

(2008) Guru Sonpavde et al.   Clinical Genitourinary Cancer

The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells

(2008) Marina Zemskova et al.   JOURNAL OF BIOLOGICAL CHEMISTRY